Melinta Therapeutics to Highlight Commitment to Antibiotics and Product Portfolio at MAD-ID 2018 Annual Meeting
08 mai 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., May 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics Receives Up to $6.2 Million from CARB-X to Advance Clinical Development of a Novel Antimicrobial to Combat Antibiotic-Resistant Bacteria
07 mai 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., May 07, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat serious...
Melinta Therapeutics to Report First Quarter 2018 Financial Results on May 8, 2018
27 avr. 2018 16h15 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., April 27, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics Presents Results from VABOMERE TANGO II Trial at ECCMID 2018, Highlighting Outcomes in Vulnerable Patient Populations
23 avr. 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics Presents Updates on the Pyrrolocytosine Compound RX-P2382 against ESKAPE Pathogens at ECCMID 2018
23 avr. 2018 07h30 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., April 23, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics to Present Detailed Results from Vabomere TANGO II Trial as well as New In Vitro and In Vivo Findings from Baxdela and Pyrrolocytosine Candidate at ECCMID 2018
16 avr. 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., April 16, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company discovering, developing and commercializing novel antibiotics to treat...
Melinta Therapeutics to Present at Needham & Company’s 17th Annual Healthcare Conference
14 mars 2018 08h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., March 14, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Cancels Presentation at The Cowen & Company 38th Annual Health Care Conference Due to Inclement Weather
13 mars 2018 16h35 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., March 13, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...
Melinta Therapeutics Reports Fourth Quarter and Full Year 2017 Financial Results
13 mars 2018 07h00 HE
|
Melinta Therapeutics
Baxdela™(delafloxacin) Launched February 6, 2018, in U.S. for Adults with ABSSSI Acquired Infectious Disease Business from The Medicines Company on January 5, 2018 First Earnings Report as a Public...
Melinta Therapeutics Partner, Menarini Group, Submits Marketing Authorization Application for Delafloxacin in Europe
08 mars 2018 07h00 HE
|
Melinta Therapeutics
NEW HAVEN, Conn., March 08, 2018 (GLOBE NEWSWIRE) -- Melinta Therapeutics, Inc. (NASDAQ:MLNT), a commercial-stage company developing and commercializing novel antibiotics to treat serious bacterial...